Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

PERPHENAZINE

All products: not a benefit

Other products in the same Health Canada class (N05A, N05AB) — coverage varies; not interchangeable

  • Fluphenazine (Moditen HCL): general benefit, Not a benefit
  • Prochlorperazine (Prochlorazine): general benefit, Not a benefit
  • Trifluoperazine (Trifluoperazine): general benefit, Not a benefit
  • Aripiprazole (Abilify Asimtufii): general benefit
  • Asenapine (Saphris): general benefit
  • Brexpiprazole (Rexulti): general benefit

18 more in the class list below

Trilafon · DIN 00028312 · 8mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1996-09-10 — choose a marketed DIN from the same-category list.Discontinued 1996-09-10 · checked 2026-09-20
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1996-09-10 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 1996-09-10 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Trilafon · DIN 00028312 Manufacturer: Schering Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 1996-09-10 · brand TRILAFON TAB 8MG · ATC N05AB03 PERPHENAZINE · form Tablet · route Oral · ingredients PERPHENAZINE 8 MG/TAB · company Schering-plough canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Trilafon: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=377 · Verify on the e-Formulary ↗ (DIN 00028312)

Source record
DIN 00028312: Trilafon Raw flags: notABenefit=Y, sec3=Y Item: 281608055; group id 503; item number 1310; lccId None; manufacturer id SCH Source form: Tab; strength: 8mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00028312 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=377
Interchangeable products
Perphenazine · DIN 00335118 · $0.0908
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 1996-09-10 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (28:16:08 Tranquilizers) and how they are covered

Matched class: 28:16:08 Tranquilizers

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ARIPIPRAZOLE, ASENAPINE, BREXPIPRAZOLE, CARIPRAZINE, FLUPENTIXOL DECANOATE, FLUPENTIXOL DIHYDROCHLORIDE, PALIPERIDONE, PALIPERIDONE PALMITATE, PERICYAZINE, PIMOZIDE, ZIPRASIDONE HCL MONOHYDRATE, ZUCLOPENTHIXOL DECANOATE, ZUCLOPENTHIXOL DIHYDROCHLORIDE Some products covered without a code (check the product listing): ALPRAZOLAM, BROMAZEPAM, CHLORDIAZEPOXIDE, CHLORPROMAZINE, CLORAZEPATE DIPOTASSIUM, DIAZEPAM, FLUPHENAZINE HCL, HALOPERIDOL, HALOPERIDOL DECANOATE, LORAZEPAM, LOXAPINE SUCCINATE, LURASIDONE HYDROCHLORIDE, OLANZAPINE, OXAZEPAM, PROCHLORPERAZINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE 28:16:08 Tranquilizers

FLUPHENAZINE HCL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 1mg, 2mg, 5mg · Tab

PROCHLORPERAZINE

· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 5mg, 10mg · Tab

TRIFLUOPERAZINE

· 8 products · General benefit (4), Listed, not a benefit (4) · strengths: 1mg, 2mg, 5mg, 10mg · Tab

ARIPIPRAZOLE

· 70 products · General benefit · strengths: 720mg/2.4mL, 960mg/3.2mL, 300mg/Vial, 400mg/Vial, 2mg, 5mg, 10mg, 15mg, 20mg, 30mg · Inj Sol-Pref Syr, Prolong-Rel Inj Pd-Vial Pk, Tab

ASENAPINE

· 2 products · General benefit · strengths: 5mg, 10mg · SL Tab

BREXPIPRAZOLE

· 6 products · General benefit · strengths: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg · Tab

CARIPRAZINE

· 4 products · General benefit · strengths: 1.5mg, 3mg, 4.5mg, 6mg · Cap

CHLORPROMAZINE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 25mg, 50mg, 100mg · Tab

FLUPENTIXOL DECANOATE

· 2 products · General benefit · strengths: 20mg/mL, 100mg/mL · Inj Sol-1mL Amp Pk

FLUPENTIXOL DIHYDROCHLORIDE

· 2 products · General benefit · strengths: 0.5mg, 3mg · Tab

HALOPERIDOL

· 14 products · Listed, not a benefit (7), General benefit (7) · strengths: 5mg/mL, 0.5mg, 1mg, 2mg, 5mg, 10mg, 20mg · Inj Sol-1mL Pk, Tab

LOXAPINE SUCCINATE

· 8 products · Listed, not a benefit (4), General benefit (4) · strengths: 5mg, 10mg, 25mg, 50mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:08 and 21 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: manifestations of psychotic disorders
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. FLUPHENAZINE HCL · Listed, not a benefit (3), General benefit (3) 1 INDICATIONS FLUPHENAZINE (fluphenazine hydrochloride) is indicated for: • Management of manifestations of psychotic disorders. PM: https://pdf.hres.ca/dpd_pm/00069653.PDF; date DEC 31, 1977; DIN 00405345; fetched 2026-09-10 Product monograph PROCHLORPERAZINE · General benefit (2), Listed, not a benefit (2) Indications PROCHLORAZINE (Prochlorperazine Maleate Tablets) is indicated for: • the management of manifestations of psychotic disorders such as agitation, confusion, delusion, tension and anxiety. PM: https://pdf.hres.ca/dpd_pm/00082835.PDF; date 2025-12-15; DIN 00886432; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1. Indications PERPHENAZINE (perphenazine tablets) is indicated for: • Management of manifestations of psychotic disorders. • Controlling nausea and vomiting due to stimulation of the chemoreceptor trigger zone. PERPHENAZINE has not been shown effective for the management of behavioral complications in patients with intellectual developmental disorder. 1.1. Pediatrics Pediatrics (<13 years of age): No data are available to Health Canada regarding use in children under 13 years of age; therefore, Health Canada has not authorized an indication for pediatric use in children under 13 years of age. See 7.1.3 Pediatrics and 4.1 Dosage Considerations. 1.2. Geriatrics Geriatrics (>55 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. See 3 Serious Warnings and Precautions Box and 7.1.4 Geriatrics. https://pdf.hres.ca/dpd_pm/00084763.PDF PM date: May 15, 2026 Source product: PERPHENAZINE; DIN 00335096; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Trilafon: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026